Contact your healthcare provider, visitwww.PulmozymeCoPayCard.com, or call , the makers of Pulmozyme® (dornase alfa) Inhalation Solution, is committed to helping all patients access our medicines, regardless of their ability to pay. That is why we are introducing the Pulmozyme Access Solutions Co-Pay Card Program, designed to help pay for Pulmozyme monthly co-pay costs. () for more information and eligibility requirements.
Also, for coverage and reimbursement support, patient assistance, and informational resources, visitwww.PulmozymeAccessSolutions.com.
For more information about Pulmozyme, visitwww.Pulmozyme.com, or see the Pulmozyme full prescribing information.
Please see Important Safety Information below and accompanying Prescribing Information.
Daily administration of Pulmozyme along with standard therapies is indicated in the management of patients to improve lung function. In patients with a forced vital capacity (volume of air exhaled with maximum effort and speed) greater than or equal to 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of requiring the administration of injectable antibiotics. In our pivotal study, safety and efficacy of daily administration has not been studied in patients beyond 12 months.
Important Safety Information
Pulmozyme should not be used in patients who are allergic to any of its ingredients. Pulmozyme should be used in conjunction with standard therapies for CF. When starting Pulmozyme therapy, patients may experience change in or loss of voice, discomfort in the throat, chest pain, red , rash, dizziness, fever, or . These side effects are usually mild and short-lived. If you experience any of the above, please report them to your doctor immediately.
You are encouraged to report of to the . Visitwww.fda.gov/medwatch, or call 1-800-FDA-1088.